Last. Kilian M. Gust(Medical University of Vienna)H-Index: 19
view all 11 authors...
Abstract Context Immune-checkpoint inhibitors (ICIs) are a mainstay treatment of metastatic renal cell carcinoma (mRCC). As not all patients benefit from ICIs, a biomarker-driven clinical decision-making strategy is desirable. Objective To assess the predictive value of programmed death ligand 1 (PD-L1) in mRCC patients treated with ICIs. Evidence acquisition Multiple databases were searched for articles published up to April 2020 according to the Preferred Reporting Items for Systematic Reviews...
#1Jillian Egan(MedStar Georgetown University Hospital)H-Index: 2
#2Shawn Marhamati(MedStar Georgetown University Hospital)H-Index: 1
Last. Keith J. Kowalczyk(MedStar Georgetown University Hospital)H-Index: 2
view all 10 authors...
Abstract Background Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) has been shown to improve continence. However, questions remain regarding feasibility and generalizability of technique and outcomes. Objective To compare the outcomes of 140 consecutive standard robot-assisted radical prostatectomy (S-RARP) versus RS-RARP. Design, setting, and participants A total of 70 S-RARPs were performed followed by 70 RS-RARPs. Demographic, pathologic, and functional outcomes were compared ...
Abstract Background Taxanes are the most active chemotherapy agents in metastatic castration-resistant prostate cancer (mCRPC) patients; yet, resistance occurs almost invariably, representing an important clinical challenge. Taxane-platinum combinations have shown clinical benefit in a subset of patients, but the mechanistic basis and biomarkers remain elusive. Objective To identify mechanisms and response indicators for the antitumor efficacy of taxane-platinum combinations in mCRPC. Design, se...
Last. Francesco Montorsi(UniSR: Vita-Salute San Raffaele University)H-Index: 138
view all 8 authors...
The similar clinical behavior, overlapping therapeutic patterns, and several clinical trials addressing the neoadjuvant and first-line therapy settings for bladder cancer support the call for a more uniform definition of "locally advanced" disease. We highlight the diverse therapeutic opportunities that patients with locally advanced bladder cancer may receive at present. Multimodal management, and post-therapy surgery in particular, may still have a role in selected patients.
BACKGROUND Salvage treatment for local recurrence after prior partial nephrectomy (PN) or local tumor ablation (LTA) for kidney cancer is, as of yet, poorly investigated. OBJECTIVE To classify the treatments and standardize the nomenclature of salvage robot-assisted renal surgery, to describe the surgical technique for each scenario, and to investigate complications, renal function, and oncologic outcomes. DESIGN, SETTING, AND PARTICIPANTS Sixty-seven patients underwent salvage robot-assisted re...
Modifications recommended by the International Society of Urological Pathology 2019 conference on prostate cancer grading include the mandatory reporting of cribriform pattern and intraductal carcinoma, inclusion of intraductal carcinoma grade in the Gleason score, and separate aggregate reporting for magnetic resonance imaging-targeted lesions.
#2Ciro Andolfi(U of C: University of Chicago)H-Index: 11
Last. Mohan S. Gundeti(U of C: University of Chicago)H-Index: 23
view all 4 authors...
Abstract Background To allow patients with bladder and bowel dysfunctions to achieve social continence, continent catheterizable channels (CCCs) are effective alternatives to intermittent self-catheterization and enema. Objective We aimed to describe our progressive advancement from open to robotic construction of CCCs, reporting outcomes and comparing the two approaches. Design, setting, and participants We retrospectively reviewed electronic medical records of pediatric patients who underwent ...
Last. Sarah P. Psutka(UW: University of Washington)H-Index: 19
view all 9 authors...
CONTEXT The Consensus on Therapeutic Exercise Training (CONTENT) scale assesses the therapeutic validity of exercise programs. To date, prehabilitation exercise programs for heath optimization before urologic cancer surgeries have not been assessed for therapeutic validity or efficacy. OBJECTIVE To systematically assess prehabilitation exercise programs before urologic cancer surgery for therapeutic validity and efficacy, informing discussion of best practices for future intervention. EVIDENCE A...